MCLA-128: a HER2xHER3 bispecific antibody with a novel DOCK & BLOCK® | Mechanism of Action (MOA)

How a Bispecific Antibody Could Treat NRG1+ Cancers | Merus
NRG1+ cancers are a rare and deadly form of cancer that are caused by a genetic mutation. But there is hope: a new bispecific antibody called MCLA-128 that can block the mutation and activate the immune system to fight the cancer. Watch this video to learn how MCLA-128 works, and how Merus is developing innovative bispecific antibodies for patients with NRG1+ cancers and other diseases.
Check out the complete mechanism of action (MoA) that explains how it works: • MCLA-128: a HER2xHER3 ...
#science #cancer #oncology
Did you like the video? Please support and LIKE, SUBSCRIBE & COMMENT!
SOURCE
merus.nl/techn...
CONNECT WITH US!
Twitter: / nymus3d
Facebook: / nymus3d
LinkedIn: / nymus-3d
Xing: www.xing.com/p...
Instagram: / nymus3d
Behance: www.behance.ne...
Artstation: www.artstation...
► For more information about us and our capabilities, please visit: nymus3d.com/

[@Stop-and-listen]

Immunotherapy is a crucial strategy for cancer treatment.

[@Nymus3D]

Agreed.